About
Trinitas Global is a research and data science company dedicated to predictive biomarker analysis through patented foundational technologies. These ground breaking technologies and supporting research of the Trinitas Risk Assessment incorporate multiple patient biomarkers to predict the likelihood of adverse immune response for patients impacted by COVID-19, with a broader applicability to a range of autoimmune disorders and chronic inflammatory diseases.
A New Approach to Identifying Immune Risk
Many patients faced with a severe response to a disease or virus such as COVID-19 suffer from an adverse hyperactive immune response (also known as a cytokine storm).In addition, COVID-19 undiagnosed Long Hauler Complications and concerns about vaccines side effects. Historically, there have been few reliable methods to identify those who are most at risk. Biomarker risk assessment toolsets and supporting solutions such as those from Trinitas Global can be used to help identify and mitigate these adverse immune responses—potentially before a patient is ever exposed or symptomatic.
Trinitas Expertise
PATENTED Biomarker Research
PATENTED Biomarker Research
PATENTED Biomarker Research
Trinitas Global has pioneered foundational research in combinatorial predictive biomarkers.
TRINITAS Risk Assessment
PATENTED Biomarker Research
PATENTED Biomarker Research
The Trinitas Risk Assessment utilizes existing biomarker data and purpose-built diagnostic panels to assess entire populations for risks of adverse immune response.
Clinical Programs
PATENTED Biomarker Research
Clinical Programs
Integrates the Trinitas Risk Assessment and full biomarker data within clinical workflows to optimize treatment pathways, link comorbidities, and improve outcomes.
Therapeutics
PATENTED Biomarker Research
Clinical Programs
Collaborates with institutional research organizations on optimal therapeutic response programs and novel treatments.